Bio-bibliographie (anglais)

Royaume-Uni

Thomas Wilson Meade

Prix Balzan 1997 pour l'épidémiologie

Pour ses travaux à la pointe du progrès dans le domaine de l’épidémiologie cardio-vasculaire, en particulier pour ce qui est du rôle joué par les facteurs de coagulation du sang dans l’incidence des maladies cardio-vasculaires. Ses recherches ont ouvert la voie à de nouvelles stratégies de prévention et de traitement.

Thomas Wilson Meade was born on January 21, 1936.

House Physician and House Surgeon, St. Bartholomew’s Hospital (1961-62); Senior House Officer and Registrar , Oxford RHB and United Oxford Hospitals (1962-63); Junior Medical Registrar, Medical College of St. Bartholomew’s Hospital (1964-65); Scientific Staff, Medical Research Council Social Medicine Unit, London Hospital (1964-67); Senior Lecturer (1967-70); Department of Public Health, London School of Hygiene and Tropical Medicine; seconded to Schieffelin Leprosy Research Sanatorium, Karigiri, South India (1969-70). Director, Medical Research Council, Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, St Bartholomew’s and the Royal London School of Medicine and Dentistry (formerly at Northwick Park Hospital) from 1970.

Member of Medical Research Council Physiological Systems and Disorders Board, Health Services Research Board and other Medical Research Council committees. Member of Wellcome Trust Physiology and Pharmacology Panel. Honorary member of Association of Physicians of Great Britain and Ireland. Awarded Medical Research Council Millennium Medal for 2002. Elected Fellow of the Royal Society 1996.

Among his most important publications in refereed journals, reviews, and book chapters, we mention:

  • Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study, T.W. Meade, S. Mellows, M.Brozovic, G.J. Miller, R.R. Chakrabarti, W.R.S. North, A.P. Haines, Y. Stirling, J.D. Imeson, S.G. Thompson. Lancet, 1986,2:533-537;
  • Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. T.W. Meade, J.D. Imeson, Y. Stirling, Lancet, 1987,2:986-988;
    MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal, 1992, 304:405-412;
  • Fibrinolytic activity, clotting factors and long term incidence of ischaemic heart disease in the Northwick Park Heart Study. T.W. Meade, V. Ruddock, Y. Stirling, R. Chakrabarti, G.J. Miller. Lancet, 1993, 342:1076-1079;
  • Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in hysterectomised women. Report from MRC’s General Practice Research Framework, T.W. Meade, principal investigator. British Medical Journal, 1996, 312:473-478.
  • Fibrinolytic activity and clotting factors in ischaemic heart disease in women. T.W.Meade, J.A. Cooper, R. Chakrabarti, G.J. Miller, Y. Stirling, D. Howarth. British Medical Journal, 1996, 312:1581
  • Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. M. Richards, T.W. Meade, S. Peart, P.J. Brennan, A.H. Mann. Journal of Neurology Neurosurgery and Psychiatry, 1997, 62:269-272;
  • Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). T.W. Meade, J.A. Cooper, G.J. Miller. Thrombosis & Haemostasis, 1997, 926-929;
    Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. A report from the MRC’s General Practice Research Framework. Lancet, 1998, 351:233-241;
  • Clinical examination for abdominal aortic aneurysm in general practice; report from the Medical Research Council’s General Practice Research Framework. S.R. Zuhrie, P.J. Brennan, T.W. Meade, M.R. Vickers. British Journal of General Practice, 1999, 49:731-732;
  • In: Climate Change and Human Health. A discussion meeting held at the Royal Society on 20 October 1998. Third in a series of publications on Science in Society. T.W. Meade. The Royal Society (ISBN 0 85403 525 7);
  • Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. T.W. Meade, P.J. Brennan. British Medical Journal, 2000, 321:13-17;
  • Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. J.A. Wedzicha, T.A.R. Seemungal, P.K. MacCallum, E.A. Paul, G.C. Donaldson, A. Bhowmik, D.J. Jeffries, T.W. Meade. Thrombosis & Haemostasis, 2000, 84:210-215;
  • Minimum effective intensity of oral anticoagulant therapy in primary prevention of coronary heart disease. P.K. MacCallum, P.J. Brennan, T.W. Meade. Archives of Internal Medicine. 2000, 160:2462-2468;
  • Epidemiology and prevention of ischaemic heart disease. In: Concise Oxford Textbook of Medicine. M.J. Marmot, J.I. Mann, T.W. Meade. Eds: J.G.G. Leddingham, D.A. Warrell. Oxford University Press, 2000, pp.56-63;
  • A prospective study of faecal bile acids and colorectal cancer. A. Haines, M.J. Hill, M.H. Thompson, R.W. Owen, R.E.O. Williams, T.W. Meade. European Journal of Cancer Prevention, 2000, 9:317-323;
  • Venous Thrombosis – Memorandum by T.W. Meade, Minutes of evidence taken before the House of Lords Science and Technology Committee. 20 June, 2000, 174-177;
  • Psychological characteristics and fatal ischaemic heart disease. A. Haines, J. Cooper, T.W. Meade. Heart, 2001, 85:385-389;
  • Antithrombotic agents in coronary artery disease. J.A. Cairns, P. Theroux, H.D. Lewis, M. Ezekowitz, T.W. Meade. Chest, 2001, 119 (Suppl.): 228S-252S.

(January 2002)

Vous voulez vous inscrire ou inscrire un ami à la newsletter de la Fondation Balzan?

Prénom
Nom
Email
Je, soussigné(e), déclare avoir lu et compris la notice d'information conformément au Règlement UE 2016/679 notamment en ce qui concerne mes droits et donne mon consentement au traitement de mes données personnelles de la manière et aux fins indiquées dans la notice d'information.
Fondazione Internazionale Premio Balzan